- CRH chief executive tops list of deals
- Ex-GSK director sells stock awarded in 2020
- Redde Northgate chief also cashes in
In a quiet week for director deals one or two trades stood out, firstly the decision by Albert Manifold, chief executive of building materials firm CRH (CRH), to sell 58,346 shares at €51.48 last week, raising €3 million in proceeds.
CRH’s Dublin-listed shares are up 43% this year, recently hitting a multi-year high of €54, while its London quote is due to cease on 25 September after the firm moves its primary listing to New York.
The firm argues the move to Wall Street ‘will bring increased commercial, operational and acquisition opportunities for our business, further accelerating our successful integrated solutions strategy and delivering even higher levels of profitability, returns and cash for our shareholders’.
FORMER PHARMA EXEC CASHES IN OPTIONS
Meanwhile, former GSK (GSK) executive Dr Hal Barron to exercise some of the nil-cost options from his 2020 pay award and offload them in the market.
Latest Issue
- Investments for decades to come. Identifying three stocks and a trust which would suit an investor with long-term horizons.
- Plus, Warren Buffett in focus after the latest Berkshire Hathaway AGM and what upcoming Home Depot earnings could reveal about the US consumer.
- Read articles on how to find lost or forgotten Child Trust Funds as well as how Junior ISAs could be used to build a up a pot of cash to cover the costs of your children’s further education.
- Also in the digital magazine: a market comparison between South Korea and Japan and investment ideas on a quality construction company and investment trust focused on great businesses going cheap.
Barron, who until March 2022 was chief scientific officer and president of R&D (research and development) at GSK, cashed in 155,206 ADS (American depository shares) at an average price of $17.31 to net a comfortable $2.67 million.
After leaving the UK firm in March last year, Barron took on the role of chief executive and chairman at US cellular technology company Altos Labs.
